Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277702 | 0.85 | ALDH1A1 (0.53) | MAOBMAOAALDH1A1 | |
| SCHEMBL5648170 | 0.85 | MAPK1 (0.59) | MAOBRARARARBMAOANR1H4 | |
| SCHEMBL2958827 | 0.83 | NR1H4 (0.51) | NR1H4ALDH1A1TARBP2 | |
| SCHEMBL13366264 | 0.82 | RARA (0.55) | MAOBRARARARBMAOAALDH1A1 | |
| SCHEMBL18648451 | 0.82 | NR1H4 (0.45) | NR1H4ALDH1A1 | |
| SCHEMBL21327850 | 0.81 | NR1H4 (0.47) | NR1H4ALDH1A1TARBP2 | |
| SCHEMBL9197144 | 0.81 | TSHR (0.47) | NR1H4ALDH1A1 | |
| SCHEMBL2590126 | 0.80 | ALDH1A1 (0.71) | MAOBRARARARBMAOAALDH1A1 | |
| SCHEMBL18793210 | 0.80 | MAOB (0.51) | MAOBRARARARBMAOA | |
| SCHEMBL8493184 | 0.79 | NR1H4 (0.48) | NR1H4ALDH1A1TARBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| CN-101284865-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-10-15 | — | — | CN | disclosed |
| CN-100378063-C | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | MAOB 4012/4885RARA 2931/4885RARB 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.